70.81

5.68% 3.83

Exact Sciences Corp (EXAS)

Overview News Price History Option Chain Financials Discussions Forecast

Exact Sciences Corp stock is traded at $70.81, with a volume of 4.34M. It is up +5.68% in the last 24 hours and up +24.79% over the past month. Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Previous Close:

$66.98

Open:

$70.08

24h Volume:

4.34M

Relative Volume:

1.47

Market Cap:

$13.44B

Revenue:

$2.83B

Net Income/Loss:

$-1.02B

P/E Ratio:

-12.85

EPS:

-5.51

Net Cash Flow:

$194.14M

1W Performance:

+11.82%

1M Performance:

+24.79%

6M Performance:

+37.31%

1Y Performance:

-0.49%

1-Day Range:

$67.61

$72.81

1-Week Range:

$62.54

$72.81

52-Week Range:

$38.81

$72.83

Exact Sciences Corp Stock (EXAS) Company Profile

Name

Exact Sciences Corp

Sector

Healthcare (1141)

Industry

Diagnostics & Research (53)

Phone

608-284-5700

Address

5505 ENDEAVOR LANE, MADISON, WI

Employee

7,000

Twitter

@exactsciences

Next Earnings Date

2024-11-05

Latest SEC Filings

EXAS's Discussions on Twitter

Compare EXAS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EXAS Exact Sciences Corp	70.97	12.68B	2.83B	-1.02B	194.14M	-5.51
TMO Thermo Fisher Scientific Inc	568.64	212.23B	43.74B	6.58B	6.11B	17.31
DHR Danaher Corp	214.94	151.20B	24.27B	3.50B	5.02B	4.8589
IDXX Idexx Laboratories Inc	720.05	57.84B	4.04B	985.66M	774.34M	12.01
A Agilent Technologies Inc	148.43	41.02B	6.79B	1.22B	1.09B	4.2644
IQV Iqvia Holdings Inc	215.29	36.42B	15.90B	1.28B	2.21B	7.2842

Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-25	Initiated	Mizuho	Outperform
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform
Jan-23-25	Initiated	Barclays	Overweight
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-27-24	Initiated	Scotiabank	Sector Outperform
Jun-03-24	Resumed	Jefferies	Buy
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Sep-28-23	Initiated	Bernstein	Outperform
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy
May-05-23	Initiated	UBS	Neutral
Mar-09-23	Upgrade	Citigroup	Neutral → Buy
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold
Aug-25-22	Initiated	Credit Suisse	Outperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Nov-03-21	Downgrade	Raymond James	Strong Buy → Outperform
Jul-29-21	Reiterated	BTIG Research	Buy
Jul-29-21	Reiterated	Canaccord Genuity	Buy
Jul-29-21	Reiterated	Oppenheimer	Outperform
Jul-29-21	Reiterated	Stifel	Buy
Jun-15-21	Initiated	Raymond James	Strong Buy
Jun-03-21	Initiated	Goldman	Buy
May-25-21	Initiated	Wells Fargo	Equal Weight
Jan-28-21	Initiated	Truist	Buy
Oct-29-20	Downgrade	UBS	Buy → Neutral
Oct-28-20	Downgrade	Citigroup	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Apr-02-20	Initiated	Evercore ISI	Outperform
Jan-10-20	Resumed	BTIG Research	Buy
Jan-07-20	Initiated	Citigroup	Buy
Dec-13-19	Initiated	Dougherty & Company	Buy
Nov-15-19	Initiated	Stifel	Buy
Oct-17-19	Reiterated	BofA/Merrill	Buy
Oct-01-19	Resumed	Craig Hallum	Buy
Sep-26-19	Initiated	Oppenheimer	Outperform
Feb-26-19	Upgrade	Goldman	Neutral → Buy
Oct-09-18	Initiated	UBS	Buy
Sep-05-18	Resumed	The Benchmark Company	Hold
Aug-13-18	Reiterated	Canaccord Genuity	Buy
Apr-03-18	Upgrade	BTIG Research	Neutral → Buy
Jan-29-18	Initiated	Goldman	Neutral
Jan-08-18	Reiterated	The Benchmark Company	Buy
Nov-13-17	Downgrade	Robert W. Baird	Outperform → Neutral
Nov-01-17	Downgrade	BTIG Research	Buy → Neutral

View All

Exact Sciences Corp Stock (EXAS) Latest News

10:20 AM

Stifel raises Exact Sciences stock price target to $80 on strong Cologuard growth - Investing.com

10:20 AM

09:39 AM

EXAS: Barclays Raises Price Target to $77, Maintains Overweight Rating | EXAS Stock News - GuruFocus

09:39 AM

09:25 AM

These Analysts Raise Their Forecasts On Exact Sciences Following Better-Than-Expected Q3 Results - Benzinga

09:25 AM

09:10 AM

Madison-based Exact Sciences reports Q3 results topping analysts’ expectations - Wisconsin State Journal

09:10 AM

08:07 AM

EXAS: Stifel Raises Target Price to $80, Maintains Buy Rating | - GuruFocus

08:07 AM

07:09 AM

BTIG Raises Price Target for Exact Sciences (EXAS) to $85 | EXAS Stock News - GuruFocus

07:09 AM

07:05 AM

Exact Sciences stock price target raised to $85 from $75 at BTIG - Investing.com

07:05 AM

07:00 AM

Exact Sciences to Participate in November Investor Conference - Business Wire

07:00 AM

06:43 AM

How Intuitive Surgical Stock Gained 19.5% Last Month - AOL.com

06:43 AM

05:28 AM

Exact Sciences Corporation stock chart pattern explained2025 AllTime Highs & Daily Profit Focused Screening - newser.com

05:28 AM

05:16 AM

Exact Sciences: Q3 Earnings Snapshot - New Haven Register

05:16 AM

04:08 AM

Canaccord Genuity raises Exact Sciences stock price target to $85 on strong growth - Investing.com

04:08 AM

03:27 AM

Can Exact Sciences Corporation (EXK) stock stage a strong rebound this quarter2025 Short Interest & Real-Time Chart Pattern Alerts - newser.com

03:27 AM

12:09 PM

Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus

12:09 PM

12:04 PM